Identifying and Targeting Angiogenesis-related microRNAs in Ovarian Cancer


Authors: X. Chen, L.S. Mangala, L. Mooberry, E. Bayraktar, S.K. Dasari, S. Ma, C. Ivan, K.A. Court, C. Rodriguez-Aguayo, R. Bayraktar, S. Raut, N. Sabnis, X. Kong, X. yang, G. Lopez-Berestein, A.G. Lacko, and A. K. Sood

Journal: Oncogene

DOI: 10.1038/s41388-019-0862-y

Publication - Abstract

July 09, 2019

Abstract

Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein–nanoparticles (rHDL–NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Blog Posts
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Optimizing Biodegradable Nanoparticle Size for Tissue-specific Delivery

H.K. Mandl, E. Quijano, H.W. Suh, E. Sparago, S. Oeck, M. Grun, P.M. Glazer, and W.M. Saltzman

Nanoparticles (NPs) are promising vehicles for drug delivery because of their potential to target specific tissues [1]. Although it is known that NP size plays a critical role in determining their biological activity, there are few quantitative studies of the role of NP size in d...
Read More


Publication - Summary

The potency of drug delivery systems can heavily rely on their ability to penetrate poorly vascularized tissues such as tumors, following intravenous administration. The drug delivery vehicle’s size greatly impacts this phenomenon.

Read More


Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.